CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
Rhea-AI Summary
CAMP4 (Nasdaq: CAMP) entered a strategic research, collaboration and license agreement with GSK on Dec 18, 2025 to apply CAMP4’s RAP Platform® to identify antisense oligonucleotide (ASO) candidates for neurodegenerative and kidney diseases.
Under the deal CAMP4 will receive $17.5 million upfront, is eligible for additional milestone payments and tiered royalties, and will deliver discovery-stage regRNA-targeting ASOs while GSK will lead development and commercialization.
Positive
- $17.5 million upfront cash payment to CAMP4
- Potential for additional milestone payments and tiered royalties
- GSK to handle development and commercialization, reducing CAMP4 execution burden
- Use of CAMP4 RAP Platform® to generate ASO candidates for multiple targets
Negative
- CAMP4 limited to discovery-stage deliverables; GSK controls development/commercialization
- Future payments are contingent on unspecified milestones, not guaranteed
News Market Reaction 8 Alerts
On the day this news was published, CAMP declined 12.90%, reflecting a significant negative market reaction. Argus tracked a trough of -11.1% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $50M from the company's valuation, bringing the market cap to $334M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: ADVM up 2.83%, while DTIL, PDSB, and PYPD are down and CUE is flat. With no peers in the momentum scanner and no same-day peer headlines, CAMP’s move appears stock-specific to this collaboration.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 12 | Inducement option grants | Neutral | +4.0% | Inducement stock options for new hires under Nasdaq Listing Rule 5635(c)(4). |
| Nov 14 | Inducement option grant | Neutral | -2.7% | Single inducement option grant to a new employee with standard vesting terms. |
| Nov 06 | Q3 2025 earnings | Positive | +7.0% | Q3 results, runway into 2027, cash of <b>$75.3M</b>, and CMP-002/CMP-001 program updates. |
| Oct 01 | GLP tox initiation | Positive | -1.7% | Start of GLP tox for CMP-SYNGAP-01 targeting a Phase 1/2 trial in H2 2026. |
| Sep 10 | Private placement financing | Positive | +40.2% | Oversubscribed private placement of up to <b>$100M</b> to advance SYNGAP1 program. |
Recent news with clear positive fundamentals (financing, pipeline progress, earnings) has usually aligned with positive price reactions, though one pipeline update saw a mild divergence.
Over the last few months, CAMP has combined financing, pipeline progress, and corporate updates. A September private placement of up to $100M and an oversubscribed deal drove a 40.2% move. Subsequent GLP tox initiation for SYNGAP1 and Q3 2025 results, including cash of $75.3M and runway into 2027, were followed by generally positive reactions. Inducement option grants had modest mixed moves. Today’s GSK collaboration fits a pattern of external partnerships and capital access supporting its RNA-focused programs.
Regulatory & Risk Context
An effective Form S-3 shelf filed on 2025-11-10 registers up to $300,000,000 in securities and includes an ATM for up to $100,000,000 of common stock via Leerink Partners at up to a 3.0% commission. One related 424B3 usage was recorded, and the shelf is noted as not effective in the shelf context, so actual issuance capacity depends on effectiveness and future decisions.
Market Pulse Summary
The stock dropped -12.9% in the session following this news. A negative reaction despite a GSK collaboration with a $17.5M upfront payment would contrast with prior positive responses to financings and pipeline progress. Pressure from the registered resale of 33.4M shares (~69% of outstanding) and the existing $300M shelf and $100M ATM capacity could contribute to concerns about future dilution. Historical patterns show mostly aligned moves on good news, so a sharp decline could reflect overhang rather than collaboration terms alone.
Key Terms
antisense oligonucleotides medical
ASO medical
RNA-based therapeutic medical
tiered royalties financial
AI-generated analysis. Not financial advice.
Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases
CAMP4 to receive
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, has entered into a strategic research, collaboration and license agreement with GSK to identify and develop antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications.
“Protein under-expression plays a critical role in diseases such as neurodegenerative and kidney disease. Our collaboration with GSK, focused on the rapid identification of novel targets and potential ASO therapeutics that increase the expression of validated genetic targets, underscores the potential of our discovery platform to create transformational medicines for patients,” said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4.
Under the terms of the agreement, CAMP4 will receive a
CAMP4 will utilize its proprietary RAP Platform® to identify regRNAs controlling the expression of multiple gene targets and generate regRNA-targeting ASO candidates that amplify target gene expression for potential development. GSK will be responsible for the further development and commercialization of ASO drug candidates identified through the collaboration.
Chris Austin, SVP Research Technologies, GSK, said: “We are excited to collaborate with CAMP4, combining their RNA discovery platform to increase specific gene activity with GSK’s expertise in therapeutic oligonucleotides, genetics and advanced laboratory and data technologies. This agreement aims to drive the development of novel medicines for neurodegenerative and kidney disease and demonstrates our approach of harnessing cutting-edge technologies to deliver transformational therapies for patients.”
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
Forward-Looking Statements
This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning the development of ASO drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications; the potential of the Company’s platform technology; the Company’s receipt of future contingent milestones and/or royalties; and the Company’s strategy, goals, business plans and focus. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of product candidates, which is complex, and the risk that third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for current and future product; the Company’s reliance on third parties to conduct preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as well as other information the Company files with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contacts
Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com
Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com
FAQ
What did CAMP4 announce on December 18, 2025 regarding GSK?
How much cash will CAMP4 receive upfront from GSK for the collaboration (CAMP)?
Will CAMP4 get additional payments beyond the $17.5 million upfront (CAMP)?
Which disease areas are covered by the CAMP4 and GSK collaboration (CAMP)?
What role will CAMP4 play versus GSK in the partnership (CAMP)?
Does the agreement guarantee future revenue for CAMP4 shareholders (CAMP)?
